CDC Antimicrobial Resistance Threats Report

Drug-resistant *Mycobacterium tuberculosis* Data Methods

Tuberculosis (TB) is a nationally notifiable disease, meaning it must be reported to public health officials upon diagnosis; all 50 states, the District of Columbia (DC), New York City, five U.S. territories, and three freely associated states report cases to CDC's National Tuberculosis Surveillance System (NTSS). Reported cases are verified according to the TB Case Definition for Public Health Surveillance and are reported and counted according to the Recommendations for Reporting and Counting TB Cases [1]. Cases referenced in this application are limited to those reported by the 50 U.S. states and DC.

In 2023, molecular drug-susceptibility testing capabilities were available from all jurisdictions for the first time. Starting in 2023, the number of all drug-resistant cases to any of the four first-line TB drugs is calculated using both growth-based and molecular results. All TB cases without documented drug resistance include people who have no culture or no drug susceptibility testing. Estimated costs per multidrug-resistant (MDR) and extensively drug-resistant (XDR) case were based on published methods and updated to 2023 dollars [2,3]. Deaths reported to NTSS include cases diagnosed after death and deaths among patients undergoing TB treatment; death data are not available for 2022 and 2023 due to a 2-year reporting lag. Reported deaths include persons who were dead at diagnosis or died during therapy, and for whom TB or TB therapy was indicated as a cause of death [4].

NTSS allows for continuous updates to TB reporting. Variations in historical TB data are attributable to updated information submitted in the interim by reporting areas; this report includes data reported through July 17, 2024.

References

1. Centers for Disease Control and Prevention. Reported tuberculosis in the United States, 2023. Department of Health and Human Services; 2024.
2. Winston CA, Marks SM, Carr W. Estimated treatment costs for multidrug-resistant TB in the United States. *Emerg Infect Dis.* 2023; 29(10), 2102–2104. doi:10.3201/eid2910.230314
3. Marks S, Winston C. Treatment costs estimated for multidrug-resistant TB treatment, United States, 2022. *Int J Tuberc Lung Dis.* 2024; 28(4):214–215. doi:10.5588/ijtld.23.0621
4. Centers for Disease Control and Prevention. National Center for Health Statistics, Mortality Data on CDC WONDER, Multiple Cause of Death Files, 1999–2022. Accessed September 2, 2025. https://wonder.cdc.gov/mcd.html

For more information on drug-resistant *Mycobacterium tuberculosis*, visit: https://arthreats.cdc.gov/tb

Revised October 2026